Evaluation of IP-10 in blood serum for TB diagnosis in patients with late-stage HIV infection

<b>Introduction:</b> Chemokine IP-10 (CXCL-10) is an additional laboratory criterion for TB diagnosis in patients with late-stage HIV infection. <b>Aim:</b> To establish the influence of TB dissemination and sputum positivity on the blood serum IP-10 level in patients with late-stage HIV infection. <b>Materials and methods:</b> We studied 35 patients with late-stage HIV infection: 16 4B-stage patients and 19 4C-stage patients (as per Russian classification). Among them were 23 men and 12 women aged 19-62. We conducted clinical, radiology, microbiology (microscopy, PCR, BACTEC) studies. Chemokine IP-10 was determined in blood serum by enzyme-linked immunoassay using the DuoSet Human IP-10 R@D kit (UK). <b>Results:</b> TB was diagnosed in 21/35 (60%) patients with late-stage HIV infection. Disseminated processes were established in 16/21 (76.2%), limited processes – in 5/21 (23.8%), and 14/21 (66.7%) patients were sputum positive. The level of chemokine IP-10 of more than 1236.64 pg/ml in the blood serum witnessed TB in patients with late-stage HIV infection. <b>Conclusions:</b> 1) The level of chemokine IP-10 does not depend on TB dissemination (disseminated forms of TB: 2021.39 ± 465.9 pg/ml (CI±913.16 pg/ml), limited forms: 2616.25 ± 466.7 pg/ml (CI±914.7 pg/ml), р&gt;0.05); 2) The level of IP-10 depends on sputum positivity (sputum positive patients: 2713.02 ± 498.15 pg/ml (CI±967.3 pg/ml), and sputum negative patients: 988.01 ± 319.28 pg/ml (CI±625.8 pg/ml), Р=0.012103).